Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
1.99 (1y: -39%)
Market Cap 62 M P/E(ttm)
Enterprise Value 62.56 M P/B 3.50
ARWR- NAS (USA)
Arrowhead Research Corporation
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$1.99
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry		 vs
history
Cash to Debt 1.491
ARWR's Cash to Debt is ranked higher than
65% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. ARWR: 1.491 )
ARWR' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 1.49
Equity to Asset 0.606
ARWR's Equity to Asset is ranked higher than
72% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. ARWR: 0.606 )
ARWR' s 10-Year Equity to Asset Range
Min: -30.91   Max: 0.9
Current: 0.61
-30.91
0.9
F-Score: 2
Z-Score: -18.34
M-Score: -11.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) -14346.30
ARWR's Operating margin (%) is ranked lower than
61% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ARWR: -14346.30 )
ARWR' s 10-Year Operating margin (%) Range
Min: -70800   Max: -70
Current: -14346.3
-70800
-70
Net-margin (%) -14371.4
ARWR's Net-margin (%) is ranked lower than
61% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. ARWR: -14371.4 )
ARWR' s 10-Year Net-margin (%) Range
Min: -14371.4   Max: 1602.7
Current: -14371.4
-14371.4
1602.7
ROE (%) -211
ARWR's ROE (%) is ranked lower than
59% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARWR: -211 )
ARWR' s 10-Year ROE (%) Range
Min: -397.4   Max: -24.5
Current: -211
-397.4
-24.5
ROA (%) -127.8
ARWR's ROA (%) is ranked lower than
60% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ARWR: -127.8 )
ARWR' s 10-Year ROA (%) Range
Min: -404.3   Max: 723.2
Current: -127.8
-404.3
723.2
ROC (Joel Greenblatt) (%) -735.80
ARWR's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARWR: -735.80 )
ARWR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2889.8   Max: -427.3
Current: -735.8
-2889.8
-427.3
Revenue Growth (%) -67
ARWR's Revenue Growth (%) is ranked lower than
61% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARWR: -67 )
ARWR' s 10-Year Revenue Growth (%) Range
Min: -67   Max: 45
Current: -67
-67
45
EBITDA Growth (%) -19.5
ARWR's EBITDA Growth (%) is ranked lower than
55% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARWR: -19.5 )
ARWR' s 10-Year EBITDA Growth (%) Range
Min: -56.4   Max: 116.5
Current: -19.5
-56.4
116.5
EPS Growth (%) -18.5
ARWR's EPS Growth (%) is ranked lower than
55% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARWR: -18.5 )
ARWR' s 10-Year EPS Growth (%) Range
Min: -50.9   Max: 37.8
Current: -18.5
-50.9
37.8
» ARWR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ARWR Guru Trades in

ARWR Guru Trades in

ARWR Guru Trades in

Q2 2011

ARWR Guru Trades in Q2 2011

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARWR



No Insider Trades Found!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/B 3.50
ARWR's P/B is ranked higher than
69% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. ARWR: 3.50 )
ARWR' s 10-Year P/B Range
Min: 1.34   Max: 75.56
Current: 3.5
1.34
75.56
P/S 91.80
ARWR's P/S is ranked lower than
58% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. ARWR: 91.80 )
ARWR' s 10-Year P/S Range
Min: 2.44   Max: 2500
Current: 91.8
2.44
2500
EV-to-EBIT 8.1
ARWR's EV-to-EBIT is ranked higher than
71% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. ARWR: 8.1 )
ARWR' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 8.1

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 22.1
ARWR's Price/Net Current Asset Value is ranked higher than
81% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: 45.80 vs. ARWR: 22.1 )
ARWR' s 10-Year Price/Net Current Asset Value Range
Min: 5.3   Max: 55.3
Current: 22.1
5.3
55.3
Price/Tangible Book 6.6
ARWR's Price/Tangible Book is ranked higher than
62% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. ARWR: 6.6 )
ARWR' s 10-Year Price/Tangible Book Range
Min: 2.7   Max: 12.1
Current: 6.6
2.7
12.1
Price/Median PS Value 2.7
ARWR's Price/Median PS Value is ranked lower than
65% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. ARWR: 2.7 )
ARWR' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 4.9
Current: 2.7
0.1
4.9
Forward Rate of Return (Yacktman) -193.93
ARWR's Forward Rate of Return (Yacktman) is ranked lower than
60% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARWR: -193.93 )
ARWR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -60   Max: -7.5
Current: -193.93
-60
-7.5

Business Description

Arrowhead Research Corp. was originally incorporated in South Dakota in 1989, and was reincorporated in Delaware in 2000. It is a development stage nanotechnology holding company that forms, acquires, and operates subsidiaries commercializing innovative nanotechnologies. By working closely with scientists and universities, Arrowhead identifies advances in nanotechnology and matches them with product development opportunities in high-growth markets. The Company is focusing on developing and advancing a portfolio of subsidiaries in the field of nanomedicine. Arrowhead owns two majority-owned operating subsidiaries, Calando Pharmaceuticals and Unidym, Inc. and has minority investments in two early-stage nanotechnology companies, Nanotope, Inc. and Leonardo Biosystems, Inc. Arrowhead also owns two nonoperating subsidiaries, Agonn Systems, Inc. and Tego Biosciences Corporation. Arrowhead's strategy is to maintain or build a majority ownership position in each portfolio company, thus providing significant exposure to their growth. Arrowhead's ultimate goal is to monetize the value of its subsidiaries through an initial public offering of subsidiary stock or a sale of a subsidiary to another company.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:HDP1.Germany
» More Articles for ARWR

Headlines

Articles On GuruFocus.com
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 05 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Reports Third Quarter Fiscal 2009 Financial Results Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 09 2009 
Arrowhead Reports First Quarter Fiscal 2009 Financial Results Feb 09 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK